Enabling clinician and patient‐friendly genomic-reporting at a major diagnostic laboratory

With expert genetic counselors well served by the existing report, this leading lab’s value-proposition was being undercut by return-of-results friction with physicians and patients Clinicians, patients, and caregivers found existing reports difficult to parse quickly; dense text, unclear action items, and more led to delays in interpretation.  And worse yet they led to hesitancy in […]

Creating a market-leading cohort solution that drives value inflection

Researchers, data scientists, and business leaders using this market-leading tertiary platform needed to know—quickly and clearly—if the data they were exploring was worth pursuing and if it would enable critical value-inflection events like FDA submission and portfolio prioritization.  While cohort support was in place, what was missing was a purpose-built cohort solution that was intuitive, […]

Founding and running an innovation lab for a global diagnostics company

To quickly respond to the dynamic needs of this publicly-traded firm’s top business priorities, they looked to Notenda to set up and lead an innovation lab to test and validate revenue opportunities, new purchase journeys, customer experiences, commercial assets, and more. Leveraging Notenda’s Recruiting Network to fuel the innovation lab we created for this client, […]

Growing a genomic diagnostic testing business for rare disease 10X in one year

This pathbreaking rare disease diagnostics business had been and was now looking to accelerate sales. Of primary importance was unlocking untapped adoption potential with genetic counselors and pediatric neurologists. We engaged clinicians and key decision-makers, and in one month validated the top barriers in both the purchase journey and product experience.  Through rapid, iterative testing […]

Creating a platform business strategy for pharmacogenomics

AltheaDx, a pharmacogenomics company, about to receive approval from MolDx on reimbursement for it’s latest offering, needed a validated business model that balanced a vertical focus with the ability to serve many markets over time. With an initial need to secure the next round of funding, we framed the strategic positioning and messaging for their […]

Framing and launching a new, user-centered carrier test business

A global genomics company, WuXiNextCODE, had already been successful with other businesses focused on whole genome sequencing.  Their next focus was serving the NIPT market, and they looked to us to validate the key personas, critical user experience components, and then design and launch the detailed experience for parents, OB/GYNs, and additional family members.  In […]

Health system business modeling to create research cohorts within member populations

Geisinger had established themselves as a genomic sequencing leader among health systems by successfully creating its own genomic cohort from its patient members.  Several life-changing diagnoses were identified through this process, as well as best-in-class recruitment and consent.  They looked to us to help them package the best practices that would allow any health system […]

Validating and launching a revolutionary diabetes drug delivery solution

Focused on making patients’ lives easier by offering a new insulin delivery technology, Modular Medical targets the massive underserved segment that sits between self-injection and complex diabetes pump offerings.  They call this segment the “almost pumpers”, and they requested our help to identify the target personas, define the entire experience, and collaborate with them to […]

Commercial acceleration of a portfolio of oncology test solutions

This market-leading provider of both predictive and diagnostic testing needed to uncover accelerating levers in existing channels, as well as unlock new markets. We tested and validated prototype experiences across the entire customer journey, implemented impactful commercial solutions from awareness to ordering to sample return to return-of-results to referral & cross-sell.  We then put in […]

Menu